Biozeus Biopharmaceutical S.A.
5
2
2
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
1 terminated/withdrawn out of 5 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder
Role: lead
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Role: lead
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Role: lead
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
Role: lead
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
Role: lead
All 5 trials loaded